Dosing and uses of Ocufen (flurbiprofen ophthalmic)
Adult dosage forms and strengths
ophthalmic solution
- 0.03%
Prophylaxis of Intraoperative Miosis
1 gtt in eye(s) q30min beginning 2 hr before surgery (total 4 gtt per affected eye)
Pediatric dosage forms and strengths
Safety & efficacy not established
Ocufen (flurbiprofen ophthalmic) adverse (side) effects
Frequency not defined
Mild ocular stinging, irritation
May slow corneal wound healing
Fibrosis
Hyphema
Miosis
Mydriasis
Ocular hyperemia
Increased bleeding tendency of ocular tissues in conjunction with ocular surgery
Warnings
Contraindications
Hypersensitivity to ASA, NSAIDs or any components of the formulation
Cautions
Use with caution in patients with history of herpes simplex keratitis
Potential for cross-sensitivity to other NSAIDs or aspirin
Interferes with platelet aggregation and may increase bleeding of ocular tissues; use caution in patients with predisposition to bleeding
Corneal effects, including keratitis, reported Remove contact lenses before application, may reinsert 10 minutes after instilling drops
Corneal adverse reactions may occur in patients with keratitis after continued use that may result in loss of vision; discontinue use in patients with evidence of corneal epithelial damage
Use caution in patients with diabetes (may be at risk of corneal adverse effects that may result in loss of vision)
Use caution in patients with complicated ocular surgeries, corneal denervation, repeat ocular surface disease, or corneal epithelial defects
Use caution in patients with rheumatoid arthritis
Pregnancy and lactation
Pregnancy category: C
Lactation: Excretion in milk unknown; not recommended
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Ocufen (flurbiprofen ophthalmic)
Mechanism of action
Nonsteroidal anti-inflammatory agent; inhibits COX-1 and COX-2, which results in decreased formation of prostaglandin precursors; may decrease proinflammatory cytokine levels.
